---
---

# 21 U.S.C., USLM ref /us/usc/t21/s355c–1

* Portions Copyright © 2016 the authors of the https://github.com/publicdocs project.
  Use of this file is subject to the NOTICE at [https://github.com/publicdocs/uscode/blob/master/NOTICE](https://github.com/publicdocs/uscode/blob/master/NOTICE)
* See the [Document Metadata](././../../../../../..//README.md) for more information.
  This file is generated from historical government data; content and/or formatting may be inaccurate and out-of-date and should not be used for official purposes.

----------
----------

[Previous](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s355c.md) | [Next](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s355d.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355c%E2%80%931)

## § 355c–1. Report

    (a) __In general__ 

        Not later than four years after July 9, 2012, and every five years thereafter, the Secretary shall prepare and submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, and make publicly available, including through posting on the Internet Web site of the Food and Drug Administration, a report on the implementation of sections 355a and 355c of this title.

    (b) __Contents__ 

    Each report under subsection (a) shall include—

        (1) an assessment of the effectiveness of sections 355a and 355c of this title in improving information about pediatric uses for approved drugs and biological products, including the number and type of labeling changes made since July 9, 2012, and the importance of such uses in the improvement of the health of children;

        (2)

         the number of required studies under such [section 355c of this title][/us/usc/t21/s355c] that have not met the initial deadline provided under such [section 355c of this title][/us/usc/t21/s355c], including—

            (A) the number of deferrals and deferral extensions granted and the reasons such extensions were granted;

            (B) the number of waivers and partial waivers granted; and

            (C) the number of letters issued under subsection (d) of such [section 355c of this title][/us/usc/t21/s355c];

        (3) an assessment of the timeliness and effectiveness of pediatric study planning since July 9, 2012, including the number of initial pediatric study plans not submitted in accordance with the requirements of subsection (e) of such [section 355c of this title][/us/usc/t21/s355c] and any resulting rulemaking;

        (4) the number of written requests issued, accepted, and declined under such [section 355a of this title][/us/usc/t21/s355a] since July 9, 2012, and a listing of any important gaps in pediatric information as a result of such declined requests;

        (5) a description and current status of referrals made under subsection (n) of such [section 355a of this title][/us/usc/t21/s355a];

        (6) an assessment of the effectiveness of studying biological products in pediatric populations under such sections 355a and 355c of this title and [section 284m of title 42][/us/usc/t42/s284m];

        (7)

            (A) the efforts made by the Secretary to increase the number of studies conducted in the neonatal population (including efforts made to encourage the conduct of appropriate studies in neonates by companies with products that have sufficient safety and other information to make the conduct of the studies ethical and safe); and

            (B) the results of such efforts;

        (8)

            (A) the number and importance of drugs and biological products for children with cancer that are being tested as a result of the programs under such sections 355a and 355c of this title and under [section 284m of title 42][/us/usc/t42/s284m]; and

            (B) any recommendations for modifications to such programs that would lead to new and better therapies for children with cancer, including a detailed rationale for each recommendation;

        (9) any recommendations for modification to such programs that would improve pediatric drug research and increase pediatric labeling of drugs and biological products;

        (10) an assessment of the successes of and limitations to studying drugs for rare diseases under such sections 355a and 355c of this title; and

        (11)

         an assessment of the Secretary’s efforts to address the suggestions and options described in any prior report issued by the Comptroller General, Institute of Medicine, or the Secretary, and any subsequent reports, including recommendations therein, regarding the topics addressed in the reports under this section, including with respect to—

            (A) improving public access to information from pediatric studies conducted under such sections 355a and 355c of this title; and

            (B) improving the timeliness of pediatric studies and pediatric study planning under such sections 355a and 355c of this title.

    (c) __Stakeholder comment__ 

        At least 180 days prior to the submission of each report under subsection (a), the Secretary shall consult with representatives of patient groups (including pediatric patient groups), consumer groups, regulated industry, academia, and other interested parties to obtain any recommendations or information relevant to the report including suggestions for modifications that would improve pediatric drug research and pediatric labeling of drugs and biological products.

([Pub. L. 112–144, title V][/us/pl/112/144/tV], § 508, July 9, 2012, [126 Stat. 1045][/us/stat/126/1045].)

 __Codification__ 

    Section was enacted as part of the Food and Drug Administration Safety and Innovation Act, and not as part of the Federal Food, Drug, and Cosmetic Act which comprises this chapter.

 __Definition of “Secretary”__ 

    The term “Secretary” as used in this section means the Secretary of Health and Human Services, see [section 503 of Pub. L. 112–144][/us/pl/112/144/s503], set out as a note under [section 355a of this title][/us/usc/t21/s355a].

----------

[Previous](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s355c.md) | [Next](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s355d.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355c%E2%80%931)

----------
----------

[/us/usc/t21/s355c]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355c
[/us/usc/t21/s355c]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355c
[/us/usc/t21/s355c]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355c
[/us/usc/t21/s355c]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355c
[/us/usc/t21/s355a]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355a
[/us/usc/t21/s355a]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355a
[/us/usc/t42/s284m]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs284m
[/us/usc/t42/s284m]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs284m
[/us/pl/112/144/tV]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F112%2F144%2FtV
[/us/stat/126/1045]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F126%2F1045
[/us/pl/112/144/s503]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F112%2F144%2Fs503
[/us/usc/t21/s355a]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355a


